Author/Editor		Kanič, Vojko
Title		Klopidogrel in koronarna bolezen
Translated title		Clopidogrel and coronary heart disease
Type		članek
Source		In: Hojs R, Krajnc I, Pahor A, et al, editors. Zbornik predavanj in praktikum 15. srečanje internistov in zdravnikov splošne medicine Iz prakse za prakso z mednarodno udeležbo; 2004 maj 7-8; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year		2004
Volume		str. 259-66
Language		slo
Abstract		The inhibition of platelet activity decreases mortality in cardiovascular patients. The ADP antagonist clopidogrel effectively inhibits platelet activity. All patients with acute coronary syndrome (ACS) should receive clopidogrel for a minimum of nine months. If PTCA is performed, clopidogrel and aspirin should be recommended for at least one year.
Descriptors		CORONARY DISEASE PLATELET AGGREGATION INHIBITORS